Genprex, Inc.
Pharmaceutical Preparations · AUSTIN · TX
Moderate confidence (50%)
Updated Oct 17, 2026, 12:03 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Genprex, Inc. received a delisting notice from its exchange (Aug 4, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Genprex, Inc. received a delisting notice from its exchange
Aug 4, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously disclosed, on July 29, 2026, the Nasdaq Hearings Panel (the Panel ) notified Genprex, Inc. (the Company or Genprex ) that the Panel had granted the Company s request to continue the Company s listing on The Nasdaq Capital Market ( Nasdaq ) and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ). On August 4, 2026, the Company was formally notified that the Pan…”
Genprex, Inc. received a delisting notice from its exchange
Jul 29, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, the Nasdaq Hearings Panel (the Panel ) notified Genprex, Inc. (the Company or Genprex ) that it has granted the Company s request to continue the Company s listing on The Nasdaq Capital Market ( Nasdaq ) and grant an exception (the Exception ) to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ), including imposing a discretionary Panel Monitor upon the Company regaining compl…”
Genprex, Inc. received a delisting notice from its exchange
Jun 10, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 10, 2026, Genprex, Inc. ( Genprex or the Company ) received a letter (the Letter ) from the Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the Company s common stock closed at less than $1.00 per share over the previous 30 consecutive business days and as a result is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker GNPX on Nasdaq.
- SEC CIK
- 0001595248
- Website
- —
- —
- Headquarters
- AUSTIN, TX
- Also known as
- —
- Legal entities
- Genprex, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Genprex, Inc. — Pharmaceutical Preparations (SIC 2834) — AUSTIN, TX
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously disclosed, on July 29, 2026, the Nasdaq Hearings Panel (the Panel ) notified Genprex, Inc. (the Company or Genprex ) that the Panel had granted the Company s request to continue the Company s listing on The Nasdaq Capital Market ( Nasdaq ) and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ). On August 4, 2026, the Company was formally notified that the Pan…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, the Nasdaq Hearings Panel (the Panel ) notified Genprex, Inc. (the Company or Genprex ) that it has granted the Company s request to continue the Company s listing on The Nasdaq Capital Market ( Nasdaq ) and grant an exception (the Exception ) to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ), including imposing a discretionary Panel Monitor upon the Company regaining compl…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 10, 2026, Genprex, Inc. ( Genprex or the Company ) received a letter (the Letter ) from the Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the Company s common stock closed at less than $1.00 per share over the previous 30 consecutive business days and as a result is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:12 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.